Characterization of Ewing sarcoma associated cancer/testis antigens

Cancer Biology and Therapy

Volumn 14, Issue 3, 2013, Pages 254-261

  Mahlendorf, Dorothea E ^a   Staege, Martin Sebastian ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cancer testis antigens; Ewing sarcoma; Gene expression; LIPI; TET ETS

Indexed keywords

B7 ANTIGEN; CANCER TESTIS ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; CYCLIN D1; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LIPASE I ALIAS MEMBRANE ASSOCIATED PHOSPHOLIPASE A1 BETA; LYSOPHOSPHATIDIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOSPHOLIPASE A1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOKINE RELEASE; EWING SARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR GROWTH;

CANCER/TESTIS ANTIGENS; EWING SARCOMA; GENE EXPRESSION; LIPI; TET-ETS;

ANTIGENS, NEOPLASM; CALMODULIN-BINDING PROTEINS; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; PHOSPHOLIPASES A1; RNA-BINDING PROTEINS; SARCOMA, EWING; T-LYMPHOCYTES, CYTOTOXIC; TESTIS;

EID: 84874920076     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23298     Document Type: Article

References (58)

1. Staege M, Max D. Genetics and epigenetics of the TETETS translocation network. Genetics and Epigenetics 2009; 2:1-15.
2. Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangié T, et al. Long-term follow up of highdose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005; 28:301-9; PMID:15923805; http://dx.doi. org/10.1097/01.coc.0000156921.28880.e1. (Pubitemid 40800484)
3. Hawkins DS. Sarcomas gone bad: what to do about recurrent Ewing sarcoma. Pediatr Blood Cancer 2011; 57:535-6; PMID:21681926; http://dx.doi. org/10.1002/pbc.23126.
4. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007; 25:707-11; PMID:17138959; http://dx.doi. org/10.1634/stemcells.2006-0469. (Pubitemid 46354230)
5. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368; http://dx.doi.org/10.1038/nrc1669. (Pubitemid 41081387)
6. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100:2014-21; PMID:19719775; http://dx.doi. org/10.1111/j.1349-7006.2009.01303.x.
7. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37(Database issue):D816-9; PMID:18838390; http://dx.doi.org/10.1093/nar/gkn673.
8. Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, et al. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun 2008; 8:13; PMID:18752338.
9. Pfeifle C, Reinhardt K, Heins S, Burdach S, Staege MS. Development and characterization of HAT-sensitive Ewing tumour cells for immunotherapy. Anticancer Res 2009; 29:4489-96; PMID:20032396.
10. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004; 64:8213-21; PMID:15548687; http://dx.doi.org/10.1158/0008-5472.CAN-03-4059. (Pubitemid 39491758)
11. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 2008; 51:228-34; PMID:18435455; http://dx.doi.org/10.1002/pbc.21602. (Pubitemid 351877042)
12. Schmiedel BJ, Hutter C, Hesse M, Staege MS. Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells. Mol Biol Rep 2011; 38:4619-28; PMID:21132378; http://dx.doi. org/10.1007/s11033-010-0595-z.
13. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004; 26:870-81; PMID:15273989; http://dx.doi.org/10.1002/bies.20081. (Pubitemid 39128101)
14. Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009; 8:1991-6; PMID:19502792; http://dx.doi.org/10. 4161/cc.8.13.8929.
15. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009; 106:5324-9; PMID:19289832; http://dx.doi.org/10.1073/pnas.0810759106.
16. Thiel U, Pirson S, Müller-Spahn C, Conrad H, Busch DH, Bernhard H, et al. Specific recognition and inhibition of Ewing tumour growth by antigenspecific allo-restricted cytotoxic T cells. Br J Cancer 2011; 104:948-56; PMID:21407224; http://dx.doi. org/10.1038/bjc.2011.54.
17. Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res 2000; 60:4752-5; PMID:10987281.
18. Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999; 59:1445-8; PMID:10197611. (Pubitemid 29160108)
19. Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010; 24:916-32; PMID:20382729; http://dx.doi.org/10.1101/gad.1899710.
20. von Bergwelt-Baildon MS, Shimabukuro-Vornhagen A, Wendtner CM, Kondo E. Identification of native, immunogenic peptides from Cyclin D1. Leukemia 2010; 24:209-11; PMID:19741723; http://dx.doi. org/10.1038/leu.2009.184.
21. Winkler C, Steingrube DS, Altermann W, Schlaf G, Max D, Kewitz S, et al. Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses. Cancer Immunol Immunother 2012; March 15 :1-11.
22. Staege MS, Hansen G, Baersch G, Burdach S. Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 2004; 43:23-34; PMID:15170886; http://dx.doi.org/10.1002/pbc.20013. (Pubitemid 38738268)
23. Staege MS, Gorelov V, Bulankin A, Fischer U, Dumon K, Hohndorf L, et al. Stable transgenic expression of IL-2 and HSV1-tk by single and fusion tumor cell lines bearing EWS/FLI-1 chimeric genes. Pediatr Hematol Oncol 2003; 20:119-40; PMID:12554523; http://dx.doi.org/10.1080/0880010390158612. (Pubitemid 36222473)
24. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44:699-709; PMID:18294840; http://dx.doi. org/10.1016/j.ejca.2008.01.020.
25. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008; 105:20422-7; PMID:19088187; http://dx.doi. org/10.1073/pnas.0810777105.
26. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 2011; 204:351-65; PMID:21872822; http://dx.doi.org/10.1016/j. cancergen. 2011.07.008.
27. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007; 46:145-60; PMID:17459484; http://dx.doi.org/10.1016/j.plipres.2007.02.001. (Pubitemid 46654231)
28. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008; 112:1876-85; PMID:18591381; http://dx.doi. org/10.1182/blood-2008-04-150045.
29. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 21:1859-74; PMID:17611570; http://dx.doi.org/10. 1038/sj.leu.2404787. (Pubitemid 47299958)
30. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, et al. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002; 62:6187-93; PMID:12414646. (Pubitemid 35244470)
31. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi. org/10.1038/nm1100. (Pubitemid 39273730)
32. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011; 45:341-60; PMID:21954698; http://dx.doi.org/10.1016/j. yasu.2011.04.003.
33. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499-509; PMID:21531979; http://dx.doi. org/10.1182/blood-2011-01-325266.
34. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537.
35. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; PMID:22776426; http://dx.doi.org/10.1186/1479-5876- 10-141.
36. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51:1417-23; PMID:4357758.
37. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33:2643-52; PMID:4748425.
38. Hoennscheidt C, Max D, Richter N, Staege MS. Expression of CD4 on Epstein-Barr virus-immortalized B cells. Scand J Immunol 2009; 70:216-25; PMID:19703011; http://dx.doi.org/10.1111/j.1365-3083.2009.02286.x.
39. Foell JL, Volkmer I, Giersberg C, Kornhuber M, Horneff G, Staege MS. Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide. J Immunol Methods 2008; 339:99-103; PMID:18789335; http://dx.doi.org/10.1016/j.jim.2008.08.006.
40. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9; PMID:10602881; http://dx.doi. org/10.1007/s002510050595. (Pubitemid 30099526)
41. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 2006; 411:352-69; PMID:16939800; http://dx.doi.org/10.1016/S0076-6879(06)11019-8. (Pubitemid 44291435)
42. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008; 28:2125-37; PMID:18212050; http://dx.doi.org/10.1128/MCB.00740-07. (Pubitemid 351429961)
43. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009; 27:2209-16; PMID:19307502; http://dx.doi. org/10.1200/JCO.2008.19.2542.
44. Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, et al. High expression of complement component 5 (C5) at tumor site associates with superior survival in Ewing's sarcoma family of tumour patients. ISRN Oncol 2011; 2011.
45. Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012; 44:323-7; PMID:22327514; http://dx.doi.org/10. 1038/ng.1085.
46. Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012; 44:461-6; PMID:22387997; http://dx.doi. org/10.1038/ng.1107.
47. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7; PMID:22460905; http://dx.doi.org/10.1038/nature11003.
48. Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006; 7:67-80; PMID:16572319; http://dx.doi.org/10.1007/ s10048-006-0032-6.
49. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008; 10:513-26; PMID:18425120; http://dx.doi.org/10.1038/ncb1714. (Pubitemid 351627371)
50. Johnson LA, Clasper S, Holt AP, Lalor PF, Baban D, Jackson DG. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 2006; 203:2763-77; PMID:17116732; http://dx.doi.org/10.1084/jem.20051759. (Pubitemid 44833351)
51. Denis JA, Rochon-Beaucourt C, Champon B, Pietu G. Global transcriptional profiling of neural and mesenchymal progenitors derived from human embryonic stem cells reveals alternative developmental signaling pathways. Stem Cells Dev 2011; 20:1395-409; PMID:21142452; http://dx.doi.org/10.1089/scd.2010.0331.
52. Chin MH, Pellegrini M, Plath K, Lowry WE. Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. Cell Stem Cell 2010; 7:263-9; PMID:20682452; http://dx.doi.org/10.1016/j. stem.2010.06.019.
53. Wang P, Rodriguez RT, Wang J, Ghodasara A, Kim SK. Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm. Cell Stem Cell 2011; 8:335-46; PMID:21362573; http://dx.doi.org/10.1016/j. stem.2011.01.017.
54. Platts AE, Dix DJ, Chemes HE, Thompson KE, Goodrich R, Rockett JC, et al. Success and failure in human spermatogenesis as revealed by teratozoospermic RNAs. Hum Mol Genet 2007; 16:763-73; PMID:17327269; http://dx.doi.org/10.1093/ hmg/ddm012. (Pubitemid 47061623)
55. Larson BL, Ylöstalo J, Prockop DJ. Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 2008; 26:193-201; PMID:17916801; http://dx.doi.org/10.1634/stemcells. 2007-0524.
56. Schwager C, Wirkner U, Abdollahi A, Huber PE. TableButler - a Windows based tool for processing large data tables generated with high-throughput methods. BMC Bioinformatics 2009; 10:235; PMID:19640300; http://dx.doi.org/10. 1186/1471-2105-10-235.
57. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002; 18:207-8; PMID:11836235; http://dx.doi. org/10.1093/bioinformatics/18.1.207. (Pubitemid 34145055)
58. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, et al. SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 2003; 31:219-23; PMID:12519986; http://dx.doi. org/10.1093/nar/gkg014. (Pubitemid 36150369)